Summary
Transgenic and gene-targeted mouse models are powerful tools for studying the pathogenesis and prevention of hypoxic pulmonary hypertension. Many hypotheses based on the findings of in vitro cell culture studies have been proved in vivo with these models, which have significantly advanced our understanding of the pathogenesis of hypoxic pulmonary hypertension. These mouse models could also be useful for screening or testing drugs to treat or prevent hypoxic pulmonary hypertension. However, since hypoxic pulmonary hypertension may be caused by multiple genetic and environmental factors, single transgenic or gene-knockout mouse models might not reflect the complex situation of the disease. Thus, future studies on hypoxic pulmonary hypertension should focus on generating and analyzing mouse models in which multiple genes have been manipulated by transgenic or gene-targeted approaches.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ali MH, Schlidt SA, Chandel NS, Hynes KL, Schumacker PT, and Gewertz BL. Endothelial permeability and IL-6 production during hypoxia: Role of ROS in signal transduction. Am. J. Physiol. Lung Cell. Mole. Physiol. 1999; 277:L1057–L1065.
Allan CM, Taylor S, and Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J. Biol. Chem. 1997; 272:29113–29119.
Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, and Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 1992; 327:70–75.
Fagan KA, Fouty BW, Tyler RC, Morris KG, Jr., Hepler LK, Saito K, LeCras TD, Abman SH, Weinberger HD, Huang PL, McMurtry IF, and Rodman DM. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J. Clin. Invest. 1999; 103:291–299.
Fagan KA, Tyler RC, Sato K, Fouty BW, Morris DG, Jr., Huang PL, McMurtry IF, and Rodman DM. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am. J. Physiol. Lung Cell. Mole. Physiol. 1999; 277:L472–L478.
Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, and Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against the development of hypoxic pulmonary hypertension. J. Clin. Invest. 1999; 103:1509–1515.
Grehan S, Tse E, and Taylor JM. Two distal downstream enhancers direct expression of the human apolipoprotein E gene to astrocytes in the brain. J. Neurosci. 2001; 21: 812–822.
Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, and Lowe SW. An epi-allelicseries of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat. Genet. 2003; 33:396–400.
Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, Narumiya S, and Geraci MW. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am. J. Respir. Crit. Care Med. 2001; 164:314–318.
Huang Y, Liu XQ, Rall SC, Jr., and Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 1998; 273:17483–17490.
Huang Y, Rall SC, Jr., and Mahley RW. Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2. Arterioscler. Thromb. Vasc. Biol. 1997; 17:2817–2824.
Huang Y, Schwendner SW, Rall SC, Jr., and Mahley RW. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J. Biol. Chem. 1996; 271:29146–29151.
Huang Y, Schwendner SW, Rall SC, Jr., Sanan DA, and Mahley RW. Apolipoprotein E2 transgenic rabbits: Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis. J. Biol. Chem. 1997; 272: 22685–22694.
Keegan A, Morecroft I, Smillie D, Hicks MN, and MacLean MR. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension. Converging evidence using 5-HT1B-receptor knockout mice and the 5-HT1B/D-receptor antagonist GR127935. Circ Res. 2001; 89: 1231–1239.
Levi M, Moons L, Bouché A, Shapiro SD, Collen D, and Carmeliet P. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice. Circulation. 2001; 103:2014–2020.
Li D, Laubach VE, and Johns RA. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am. J. Physiol. Lung Cell. Mole. Physiol. 2001; 281:L369–L376.
Minamino T, Christou H, Hsieh C-M, Liu Y, Dhawan V, Abraham NG, Perrella MA, Mitsialis SA, and Kourembanas S. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc. Natl. Acad. Sci. U.S.A. 2001; 98:8798–8803.
Morita T, Perrella MA, Lee M-E, and Kourembanas S. Smooth muscle cell-derived carbon monoxide is a regulator of vascular cGMP. Proc. Natl. Acad. Sci. U.S.A. 1995; 92:1475–1479.
Ozaki M, Kawashima S, Yamashita T, Ohashi Y, Rikitake Y, Inoue N, Hirata K-I, Hayashi Y, Itoh H, and Yokoyama M. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension. 2000; 37:322–327.
Quinlan TR, Li D, Laubach VE, Shesely EG, Zhou N, and Johns RA. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am. J. Physiol. Lung Cell. Mole. Physiol. 2000; 279:L641–L650.
Raffaï RL, and Weisgraber KH. Hypomorphic apolipoprotein E mice. A new model of conditional gene repair to examine apolipoprotein E-mediated metabolism. J. Biol. Chem. 2002; 277:11064–11068.
Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hennighausen L, Bujard H, Fishman GI, and Conklin BR. Conditional expression and signaling of a specifically designed G i -coupled receptor in transgenic mice. Nat. Biotechnol. 1999; 17:165–169.
Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanevicz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N, Warrington JA, Fishman GI, Bernstein D, Baker AJ, and Conklin BR. Conditional expression of a G i -coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 2000; 97:4826–4831.
Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Zhang M, McManus MT, Gertler FB, Scott ML, and Van Parijs L. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 2003; 33:401–406.
Shih S-J, Allan C, Grehan S, Tse E, Moran C, and Taylor JM. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J. Biol. Chem. 2000; 275:31567–31572.
Shimano H, Yamada N, Katsuki M, Shimada M, Gotoda T, Harada K, Murase T, Fukazawa C, Takaku F, and Yazaki Y. Overexpression of apolipoprotein E in transgenic mice: Marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc. Natl. Acad. Sci. U.S.A. 1992; 89:1750–1754.
Sun J-Z, Chen S-J, Li G, and Chen Y-F. Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice. Am. J. Physiol. Lung Cell. Mole. Physiol. 2000; 279: L511–L519.
Wanstall JC, Gambino A, Jeffery TK, Cahill MM, Bellomo D, Hayward NK, and Kay GF. Vascular endothelial growth factor-B-deficient mice show impaired development of hypoxic pulmonary hypertension. Cardiovasc. Res. 2002; 55:361–368.
Zaidi SHE, You X-M, Ciura S, Husain M, and Rabinovitch M. Overexpression of serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation. 2002; 105:516–521.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Huang, Y. (2004). Transgenic and Gene-Targeted Mouse Models in Hypoxic Pulmonary Hypertension Research. In: Yuan, J.X.J. (eds) Hypoxic Pulmonary Vasoconstriction. Developments in Cardiovascular Medicine, vol 252. Springer, Boston, MA. https://doi.org/10.1007/1-4020-7858-7_32
Download citation
DOI: https://doi.org/10.1007/1-4020-7858-7_32
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7857-6
Online ISBN: 978-1-4020-7858-3
eBook Packages: Springer Book Archive